ClinicalTrials.gg
WithdrawnNCT06413511Updated Aug 27, 2025

A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease

A Phase 1 interventional study of Belantamab in Autoimmune Diseases, sponsored by GlaxoSmithKline. Withdrawn. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Autoimmune Diseases by GlaxoSmithKline — 1 open to participants now, 2 under way, 1 of them phase 3. Autoimmune Diseases · GlaxoSmithKline.

Enrollment
23rd of 25
0 · median 79
Started
2024
with 2 others
Phase 1
10 of 29
none open now
Registered
28th of 29
by date

Among the 29 studies in Autoimmune Diseases by GlaxoSmithKline, this one is the 23rd largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2024, is one of 10 in phase 1, and was the 28th registered.

Autoimmune Diseases

803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

1 of the 29 studies in Autoimmune Diseases by GlaxoSmithKline is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Autoimmune Diseases by GlaxoSmithKline, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the safety and tolerability profile of belantamab. The study will also assess how the levels of belantamab change over time and body's reaction to it in participants with stable but active autoimmune disease.

03

Conditions studied

  • Autoimmune Diseases

Keywords

  • Systemic Lupus Erythematosus
  • Belantamab (GSK2857914)
  • Autoimmune Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) from 18 to 40 kilograms per square meter (kg/m\^2) (BMI = weight/height\^2), inclusive, and body weight of >=40 kilogram (kg)
  • IgM >= lower limit of normal (LLN) (40 milligram per deciliter [mg/dL]) at initial screening visit (ISV)

Participants with systemic lupus erythematosus (SLE) must also meet the following inclusion criteria:

  • Documented clinical diagnosis of SLE according to the European League Against Rheumatism (EULAR) or American College of Rheumatology (ACR) Classification Criteria
  • Positive anti-double stranded deoxyribonucleic acid (anti-dsDNA) autoantibody and/or positive antinuclear antibody (ANA) test results, using central lab test, at ISV.
  • SLE Disease Activity Index 2000 (SLEDAI-2K) total score of >=6 at ISV.
  • Failure to adequately respond to at least two therapies.

Participants with Rheumatoid Arthritis (RA) must also meet the following inclusion Criteria:

  • Meets ACR/EULAR 2010 RA Classification Criteria with a duration of RA disease of >=6 months at time of ISV
  • Positive rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) test results, using central lab test, at ISV.
  • Have moderate to severe active disease as defined by >=3/68 Tender and >=3/66 Swollen joint count at ISV and Baseline.
  • Failure to adequately respond to at least two immunosuppressive therapies.

Participants with antiphospholipid syndrome (APS) must also meet the following inclusion criteria:

  • Documented diagnosis of APS meeting the 2023 ACR/EULAR APS classification criteria
  • Positive lupus anticoagulant test or moderate to high titers of positive IgG/IgM anticardiolipin (aCL) or moderate to high titers of IgG/IgM anti-beta2-glycoprotein I antibody using central lab test, at ISV
  • Clinical features attributable to antiphospholipid antibodies that are resistant to warfarin and/or heparin:

    • Thrombotic event within last 18 months despite adequate anti-coagulation therapy and/or
    • Persistent thrombocytopenia and/or
    • Persistent hemolytic anemia
  • Sex and /Barrier requirements for females.

Exclusion criteria

Exclusion criteria:

SLE specific exclusion:

  • Any acute, severe lupus related flare during the Screening Period that needs immediate treatment
  • Has any unstable or progressive manifestation of SLE
  • Significant, likely irreversible organ damage related to SLE

RA specific exclusions:

  • RA functional status class IV according to the ACR 1991 revised criteria
  • Adult Juvenile RA

APS specific exclusions:

  • Acute thrombosis (arterial or venous acute thrombosis diagnosis) less than 30 days before study ISV
  • Catastrophic APS classification within the prior 90 days of ISV
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Belantamab

    Biological: Belantamab

Interventions

  • BiologicalBelantamab

    Belantamab will be administered

    Also known as: GSK2857914

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Up to Week 12

  2. Number of participants with clinically important findings in vital signs

    Time frame: Up to Week 12

  3. Number of participants with clinically important findings in electrocardiogram

    Time frame: Up to Week 12

  4. Number of participants with clinically important findings in echocardiogram

    Time frame: Up to Week 12

  5. Number of participants with clinically important findings in hematology

    Time frame: Up to Week 12

  6. Number of participants with clinically important findings in clinical chemistry

    Time frame: Up to Week 12

  7. Number of participants with clinically important findings in urinalysis parameters

    Time frame: Up to Week 12

  8. Number of participants with clinically important finding in corneal toxicity

    Time frame: Up to Week 12

Secondary outcomes

  1. Change from Baseline in Immunoglobulin (Ig) M (IgM)

    Time frame: Baseline (Day 1) and up to Week 12

  2. Area under the concentration-time curve from time 0 to the last quantifiable concentration [AUC(0-t)] of belantamab

    Time frame: Up to 12 weeks

  3. Area under the concentration-time curve from time 0 to infinity [AUC(0-inf)] of belantamab

    Time frame: Up to 12 weeks

  4. Maximum observed plasma drug concentration [Cmax] of belantamab

    Time frame: Up to 12 weeks

  5. Number of participants with Anti-Drug Antibodies (ADAs) against belantamab

    Time frame: Up to 12 weeks

  6. Titers of ADAs against belantamab

    Time frame: Up to 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Jul 2025, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
May 14, 2024
StartActual
Jun 3, 2024
Primary completionActual
Jul 8, 2025
CompletionActual
Jul 8, 2025
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06413511
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 14, 2024
Start date
Jun 3, 2024
Primary completion
Jul 8, 2025
Completion
Jul 8, 2025
Last update
Aug 27, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belantamab

Start the discussion